HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Asensus Surgical (AMEX:ASXC) with a Buy and maintains $3 price target.
CORRECTION: Phathom Pharmaceuticals Announces Proposed Public Offering Of Common Stock; Intends To Grant The Underwriters A 30-Day Option To Purchase Up To An Additional 15% Of The Total Number Of The Shares Of Its Common Stock Offered
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it intends to offer and sell,
